Dr. Deborah Dunsire named new President and CEO of Lundbeck
02 juil. 2018 02h41 HE
|
H. Lundbeck A/S
Valby, Denmark, 2 July 2018 - H. Lundbeck A/S (Lundbeck) today announced that the Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Dr. Dunsire...
Positive kliniske fase III-resultater med vortioxetin i japanske patienter med svær depression (MDD)
08 juin 2018 11h24 HE
|
H. Lundbeck A/S
Nye kliniske fase III-data fra et studie udført i Japan, påviser effekt af vortioxetin i forhold til placebo ved behandling af MDD hos voksne japanske patienter
De positive resultater indikerer, at...
Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder
08 juin 2018 11h24 HE
|
H. Lundbeck A/S
New clinical phase III data from a study conducted in Japan demonstrate the efficacy of vortioxetine compared to placebo for the treatment of Major Depressive Disorder (MDD) in Japanese...
Lundbeck og det amerikanske Justitsministerium (Department of Justice) er blevet enige om hovedpunkterne for en aftale
06 juin 2018 14h56 HE
|
H. Lundbeck A/S
Valby, Danmark, 6. juni 2018 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort, at selskabets amerikanske datterselskab, Lundbeck LLC, har indgået en aftale med det amerikanske Justitsministerium...
Lundbeck reaches voluntary agreement in principle with U.S. Department of Justice
06 juin 2018 14h56 HE
|
H. Lundbeck A/S
Valby, Denmark, 6 June 2018 - H. Lundbeck A/S (Lundbeck) today announced that its U.S. subsidiary Lundbeck LLC has reached an agreement in principle to resolve the U.S. Department of Justice (DOJ)...
Lundbecks og Otsukas Rxulti® (brexpiprazol) får positiv udtalelse vedrørende godkendelse i EU
01 juin 2018 08h53 HE
|
H. Lundbeck A/S
Pressemeddelelse Valby den 1. juni 2018 En endelig afgørelse fra EU Kommissionen ventes i løbet af 67 dage. H. Lundbeck A/S (Lundbeck) og Otsuka...
Lundbeck and Otsuka’s Rxulti® (brexpiprazole) receives positive opinion in EU from CHMP for the treatment of schizophrenia in adults
01 juin 2018 08h53 HE
|
H. Lundbeck A/S
Press release Valby, 1 June 2018 A final decision from the European Commission is expected within 67 days. H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce...
Kapitalforhøjelse i Lundbeck med 41.946 aktier (0,0211 % af udestående aktier) som følge af warrant-program for medarbejdere
23 mai 2018 05h22 HE
|
H. Lundbeck A/S
Valby, Danmark, 23. maj 2018 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort beslutningen om at udvide aktiekapitalen med DKK 209.730 som følge af udnyttelsen af medarbejder-warrants. ...
Lundbeck increases its share capital by 41,946 shares (0.0211 % of outstanding shares) as a result of exercise of employee warrants
23 mai 2018 05h22 HE
|
H. Lundbeck A/S
Valby, Denmark, 23 May 2018 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 209,730 as a consequence of the exercise of employee warrants. The...
Lundbeck realized 14% growth in revenue (local currency) and 103% growth in EPS
08 mai 2018 01h42 HE
|
H. Lundbeck A/S
HIGHLIGHTS Revenue reached DKK 4,585 million in the first quarter of 2018 representing an increase of 9% (14% in local currencies) compared to the same period in 2017 Revenue of Abilify...